

## **Product datasheet for TR305117**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## CysLT2 (CYSLTR2) Human shRNA Plasmid Kit (Locus ID 57105)

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** CysLT2 (CYSLTR2) Human shRNA Plasmid Kit (Locus ID 57105)

**Locus ID:** 57105

Synonyms: CYSLT2; CYSLT2R; GPCR21; HG57; hGPCR21; HPN321; KPG\_011; PSEC0146

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection: Format:

Retroviral plasmids

Components: CYSLTR2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

57105). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 001308465, NM 001308467, NM 001308468, NM 001308469, NM 001308470,

NM 001308471, NM 001308476, NM 020377, NM 020377.1, NM 020377.2, NM 020377.3,

NM 020377.4, BC069160, BC096832, NM 020377.5

UniProt ID: Q9NS75

Summary: The cysteinyl leukotrienes LTC4, LTD4, and LTE4 are important mediators of human bronchial

asthma. Pharmacologic studies have determined that cysteinyl leukotrienes activate at least 2  $\,$ 

receptors, the protein encoded by this gene and CYSLTR1. This encoded receptor is a member of the superfamily of G protein-coupled receptors. It seems to play a major role in

endocrine and cardiovascular systems. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).